Gaia Barisione

Gaia Barisione

Auto-generated profile, based on publicly available information

Gaia Barisione

Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2017 in Cancer and Metastasis Reviews
Verified
Journal Article
Open access
PDF file
AAAdriana Agnese Amaro
Adriana Agnese Amaro
RGRosaria Gangemi
Rosaria Gangemi
FPFrancesca Piaggio
Francesca Piaggio
GAGiovanna Angelini
Giovanna Angelini
GBGaia Barisione
Gaia Barisione
Ulrich PfefferUlrich Pfeffer
Ulrich Pfeffer
Uveal melanoma (UM), a rare cancer of the eye, is distinct from cutaneous melanoma by its etiology, the mutation frequency and profile, and its clinical behavior including resistance to targeted therapy and immune checkpoint blockers. Primary disease is efficiently controlled by surgery or radiation therapy, but about half of UMs develop distant metastasis mostly to the liver. Survival of patients with metastasis is below 1 year and has not improved in decades. Recent years have brought a deep understanding of UM biology characterized by initiating mutations in the G proteins GNAQ and GNA11. Cytogenetic alterations, in particular monosomy of chromosome 3 and amplification of the long arm of chromosome 8, and mutation of the BRCA1-associated protein 1, BAP1, a tumor suppressor gene, or the splicing factor SF3B1 determine UM metastasis. Cytogenetic and molecular profiling allow for a very precise prognostication that is still not matched by efficacious adjuvant therapies. G protein signaling has been shown to activate the YAP/TAZ pathway independent of HIPPO, and conventional signaling via the mitogen-activated kinase pathway probably also contributes to UM development and progression. Several lines of evidence indicate that inflammation and macrophages play a pro-tumor role in UM and in its hepatic metastases. UM cells benefit from the immune privilege in the eye and may adopt several mechanisms involved in this privilege for tumor escape that act even after leaving the niche. Here, we review the current knowledge of the biology of UM and discuss recent approaches to UM treatment.

11 June 2009 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
RRRita Rotondo
Rita Rotondo
GBGaia Barisione
Gaia Barisione
LMLuca Mastracci
Luca Mastracci
FGFRANCESCO GROSSI
FRANCESCO GROSSI
AOAnna Maria Orengo
Anna Maria Orengo
OBOttavia Barbieri
Ottavia Barbieri

9 December 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
GCGrazia Carbotti
Grazia Carbotti
GBGaia Barisione
Gaia Barisione
IAIrma Airoldi
Irma Airoldi
Delia MezzanzanicaDelia Mezzanzanica
Delia Mezzanzanica
Marina  Bagnoli Marina Bagnoli
Marina Bagnoli
SFSilvano Ferrini
Silvano Ferrini
IL-27 induces the expression of IDO and PD-L1 in human cancer cells

17 February 2011 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
RRRita Rotondo
Rita Rotondo
MBMaria Bertolotto
Maria Bertolotto
GBGaia Barisione
Gaia Barisione
ASAstigiano Simonetta
Astigiano Simonetta
Susanna MandruzzatoSusanna Mandruzzato
Susanna Mandruzzato
OBOttavia Barbieri
Ottavia Barbieri
ARG1, expressed by human PMNs, inhibits T cell proliferation by depleting extracellular l-arginine. Here, we report that ARG1, released from gelatinase granules by PMNs, is inactive at physiological pH unless activated by factor(s) stored in azurophil granules. Whereas ARG1 exocytosis was induced by TNF-α or ionomycin, only the latter mediated the release of both granules, resulting in extracellular ARG enzyme activity at physiological pH. Furthermore, after fractionation of the different classes of granules, only the mixture of gelatinase and azurophil granules resulted in ARG1 activity at physiological pH. The use of protease inhibitors indicated the involvement of a PMSF- and leupeptin-susceptible serine protease in ARG1 processing and activation. Finally, the supernatant of viable PMNs undergoing frustrated phagocytosis, which mediates gelatinase and azurophil granule release, inhibited T cell proliferation through ARG-dependent mechanisms. In vivo, high ARG1 concentrations and increased ARG enzyme activity, sufficient to inhibit T cell proliferation, were observed in synovial fluids from RA. These findings suggest that PMNs, recruited at sites of immune complex deposition, induce ARG1-dependent immune suppression through concomitant exocytosis of gelatinase and azurophil granules.

13 January 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RGRosaria Gangemi
Rosaria Gangemi
VMValentina Mirisola
Valentina Mirisola
GBGaia Barisione
Gaia Barisione
MFMarina Fabbi
Marina Fabbi
ABAntonella Brizzolara
Antonella Brizzolara
SFSilvano Ferrini
Silvano Ferrini
Uveal melanoma is an aggressive cancer that metastasizes to the liver in about half of the patients, with a high lethality rate. Identification of patients at high risk of metastases may provide indication for a frequent follow-up for early detection of metastases and treatment. The analysis of the gene expression profiles of primary human uveal melanomas showed high expression of SDCBP gene (encoding for syndecan-binding protein-1 or mda-9/syntenin), which appeared higher in patients with recurrence, whereas expression of syndecans was lower and unrelated to progression. Moreover, we found that high expression of SDCBP gene was related to metastatic progression in two additional independent datasets of uveal melanoma patients. More importantly, immunohistochemistry showed that high expression of mda-9/syntenin protein in primary tumors was significantly related to metastatic recurrence in our cohort of patients. Mda-9/syntenin expression was confirmed by RT-PCR, immunofluorescence and immunohistochemistry in cultured uveal melanoma cells or primary tumors. Interestingly, mda-9/syntenin showed both cytoplasmic and nuclear localization in cell lines and in a fraction of patients, suggesting its possible involvement in nuclear functions. A pseudo-metastatic model of uveal melanoma to the liver was developed in NOD/SCID/IL2Rγ null mice and the study of mda-9/syntenin expression in primary and metastatic lesions revealed higher mda-9/syntenin in metastases. The inhibition of SDCBP expression by siRNA impaired the ability of uveal melanoma cells to migrate in a wound–healing assay. Moreover, silencing of SDCBP in mda-9/syntenin-high uveal melanoma cells inhibited the hepatocyte growth factor (HGF)-triggered invasion of matrigel membranes and inhibited the activation of FAK, AKT and Src. Conversely syntenin overexpression in mda-9/syntenin-low uveal melanoma cells mediated opposite effects. These results suggest that mda-9/syntenin is involved in uveal melanoma progression and that it warrants further investigation as a candidate molecular marker of metastases and a potential therapeutic target.

1 September 2015 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
GBGaia Barisione
Gaia Barisione
MFMarina Fabbi
Marina Fabbi
AGAlice Gino
Alice Gino
PQPaola Queirolo
Paola Queirolo
LOLaura Orgiano
Laura Orgiano
RGRosaria Gangemi
Rosaria Gangemi
Uveal melanoma is the most common primary tumor of the adult eye, with an incidence of 2 to 8 cases per million per year.1 Despite excellent rates of local control of the primary tumor, the survival rate of patients with uveal melanoma is not good, with a mortality rate of up to 50%.1 Indeed, metastatic spread to the liver, the preferential site of metastasis,2 is followed by death for 80% of the patients within 1 year.3 Although there is no standard of care for patients with metastatic disease, new targeted therapies are presently under investigation,4 and local therapy of the liver seems to significantly improve survival, in the presence of a limited number of metastatic lesions.5,6 However, current screening methods, including liver function tests and ultrasonography, do not identify metastases until the tumor burden is already large, with widespread development of liver metastases. Some liver function test results,7,8 an increase in serum levels of S100,9,10 tissue polypeptide-specific antigen,11 growth differentiation factor 15,12 osteopontin,13,14 melanoma inhibitory antigen,15 vascular endothelial growth factor,14,16 and DJ-1,17,18 and a decrease in serum levels of insulinlike growth factor 119 have been correlated with the development of metastasis. However, there is still a need for a good biomarker that indicates the presence of early metastasis of uveal melanoma.